Ética y muerte digna

This book is an study about the bill of Death with Dignity Act, written by the Andalusian Commission on Healthcare Ethics and Research. The aim of the Act would be to “establish the criteria and conditions to be adopted by the health system to guarantee adequate healthcare during life’s final process based on the prevention of suffering and respect for each person’s dignity and free choice”.

Aspectos éticos de las comunicaciones cientificas

Artículo especial. Este texto está basado en el trabajo final del Master de Bioética y Humanización de la Asistencia realizado en la Escuela de Bioética de San Juan de Dios (Sevilla), Facultad de Teología de Granada, Universidad de Comillas durante los cursos 2006-07 y 2007-08.

Ética y muerte digna, historia de una ley : El proceso de regulación jurídica de la atención sanitaria al final de la vida en Andalucía (España)

End-of-life healthcare in any part of the world is always rife with ethical conflicts and legal challenges. In this matter, the opinions and preferences of patients, family members, healthcare professionals, society as a whole and politicians may differ or diverge entirely1. Nevertheless, death comes to all eventually; it is part of human life itself. The fact remains that we will all die. Therefore, it is natural for all societies to seek the necessary consensus for guaranteeing that individuals can live, and die, in a way befitting their nature, i.e., humanely and with full dignity. This article tells the story of how the citizens of Andalusia, in the south of Spain, reached this majority consensus during the process of drafting and approving a law regulating this issue: Law 2/2010, of 8 April, on personal rights and guarantees to die in dignity.

La eutanasia en Bélgica.

The experience of the Netherlands in relation with the legalization and practice of euthanasia is better known in Spain than the Belgian experience in this matter. But the historical process of social debate in Belgium has many specific details which should be known by Spanish healthcare professionals, bioethicists, politicians and lawyers. This paper begins with a comparative analysis of both countries: Spain and Belgium and follows with a description of the milestones of the historical process of debating and, finally, passing the Belgian Law on Euthanasia in 2002. The next chapter consists of a description of the main contents of this important Law. The paper continues then with an approach to the epidemiology of the practice of euthanasia in Belgium and finishes with a description of the different positions of the actors of the process. Two positions are described more in depth: the opinion of the specialists in palliative care, and the opinion of the Catholic Church. The paper ends underlining the reason for the incorporation of the Belgian experience on euthanasia to the debate about the possibility of legalizing euthanasia in Spain.

Consideracions ètiques al voltant de la modificació genètica en els éssers humans.

Es defineix la modificació genètica en els éssers humans. S'analitza si això canviarà la naturalesa humana. Es mostren les visions ètiques al respecte.

Conocimientos y actitudes de los profesionales sanitarios en el proceso de declaración de las voluntades vitales anticipadas.

Objective: To identify the underlying interests of the Living Will Declaration (LWD) process and to determine the consensus, using a questionnaire, of the knowledge and attitudes of health professionals. Design: A study was performed in two phases using a Delphi technique with a Rand method. 1. Dimensions proposed: generation of ideas and their subsequent prioritizing; 2. Proposal andprioritizing of items grouped into blocks of Knowledge and Attitudes, developed between August 2012 and January 2013.Setting: The work was carried out by initial telephone contact with panellists, and then later by the panellists belonged to the Andalusia Public Health System.Participants: The criteria for selecting the eight components of the panel were knowledge andexperience in the field of the freedom of the patient in Andalusia. Results: The Knowledge identified included: 1 A) Legal and general aspects; 2 A) A conceptual definition; 3 A) Standardised LWD documents: 4 A) Practical experience; 5 A) Procedure and registering of the LWDs. The second block included Attitudes: 1 B) Attitudes of the professional in the application of LWDs in clinical practice, and 2 B) Attitudes of the professional in «complex» ethical scenarios The 7 panellists who finally took part proposed 165 items. After applying the prioritizing criteria, scores, and scenario selection, 58 (35.2%) items were identified as suitable scenarios. Conclusions: The proposed questionnaire included wide parcels of concepts and contents that, once validated, will help to measure the training interventions carried out on health professionals in order to improve knowledge and attitudes on the subject of LWDs.

Consideracions sobre l'objecció de consciència

De nou l’IBB, fent un veritable exercici de diàleg bioètic i volent ser present en els debats sobre les principals qüestions que plantegen les ciències de la vida i de la salut, ofereix a la societat, a través d’un document elaborat pel seu Grup Interdisciplinari de Bioètica (GIB), elements de judici entorn de l’objecció de consciència, un tema d’actualitat sobretot arran dels canvis legals sobre la interrupció de la gestació aprovats l’any 2010. Es tracta de mirar l’objecció de consciència en els seus aspectes ètics i jurídics, tenint en compte que és un dret reconegut per les societats democràtiques i liberals i, alhora, de fer palesos els possibles límits ètics i jurídics del seu exercici, sobretot en l’àmbit de la salut, i en un context d’una societat moralment plural. El document té quatre grans parts: unes reflexions ètiques entorn de l’objecció de consciència; la perspectiva jurídica; l’objecció de consciència en l’àmbit dels professionals de la salut, i situacions de possible conflicte de valors en l’àmbit sanitari, diferents de l’objecció de consciència. Aquestes quatre parts estan emmarcades, a l’inici del document, per una justificació del tema i un apunt històric sobre el seu passat i el seu present; i es tanquen proposant deu conclusions que tenen, segons es diu explícitament, valor de síntesi per comprendre la posició del GIB de l’IBB sobre l’objecció de consciència.

Cuestiones controvertidas en evaluación económica (I): perspectiva y costes de intervenciones sanitarias.

Economic evaluation of health care interventions has experienced a strong growth over the past decade and is increasingly present as a support tool in the decisions making process on public funding of health services and pricing in European countries. A necessary element using them is that agents that perform economic evaluations have minimum rules with agreement on methodological aspects. Although there are methodological issues in which there is a high degree of consensus, there are others in which there is no such degree of agreement being closest to the normative field or have experienced significant methodological advances in recent years. In this first article of a series of three, we will discuss on the perspective of analysis and assessment of costs in economic evaluation of health interventions using the technique Metaplan. Finally, research lines are proposed to overcome the identified discrepancies.

Cuestiones controvertidas en evaluación económica (II): medidas de resultado en salud de las intervenciones sanitarias

In this second article of a series of three, we will discuss using the Metaplan technique on controversial issues of health outcomes in economic evaluation of health care interventions. The four-discussion areas focus on: choice of health outcomes measures, where any outcome measure is superior to another; extrapolation and transferability of health outcomes measures, which should not be assumed the results of an EEIS of one country to another without making certain adjustments; appropriate instruments to measure quality of life in Spain, where the EQ-5D was indicated as convenient due to its widespread international use; and, indirect comparisons, where the combination of both comparisons, direct and indirect, it would be advisable if the test for indirect estimates is consistent and has been validated. Finally, research lines to try to overcome the identified discrepancies were identified in each of these areas, some of those are: doing studies of correlation between scores of specific and generic instruments measuring quality of life; update or create a database of economic evaluations in Spain; estimating utilities for the Spanish population by existing generic and specific instruments; or, establish a common way to show the results of a meta-analysis network.

Cuestiones controvertidas en evaluación económica (III). Intervenciones sanitarias en tres situaciones especiales: enfermedades raras, tratamientos al final de la vida y externalidades en las evaluaciones.

The development of the economic evaluation of health care interventions has become a support tool in making decisions on pricing and reimbursement of new health interventions. The increasingly extensive application of these techniques has led to the identification of particular situations in which, for various reasons, it may be reasonable to take into account special considerations when applying the general principles of economic evaluation. In this article, which closes a series of three, we will discuss, using the Metaplan technique, about the economic evaluation of health interventions in special situations such as rare diseases and end of life treatments, as well as consideration of externalities in assessments, finally pointing out some research areas to solve the main problems identified in these fields.

In memoriam: Dr. Francesc Abel i Fabre, SJ.

The Journal of Medicine and Philosophy has been impoverished by the loss of Dr. Francesc Abel Fabre, S.J. (1933–2011), one of the founders of bioethics and a long-time member of the Editorial Advisory Board. 2011 brought the death of Dr. Francesc Abel Fabre, S.J., at the age of 78. He was the pioneer of European bioethics. Dr. Abel learned the discipline at Georgetown University, working side by side with the founder and first director of the Kennedy Institute of Ethics, André Hellegers, as bioethics itself was coming into existence. He went from this experience to establish the Institute Borja of Bioethics in Catalonia in 1976, the first center of bioethics in Spain and in Europe. Through his scholarship and teaching, he established an influential dialogue in bioethics, as well as ethics committees in hospitals and in research centers. In 1986 he joined in founding the European Association of Centres of Medical Ethics, an organization in which he was involved and participated for the last 25 years. He contributed crucially to bioethics across the world, especially through the International Study Group on Bioethics (1980–1994). He was widely recognized as an outstanding bioethics expert in Latin America.